MARUHO CO., LTD.

Journey Medical Corporation announced FDA approval of Emrosi™ for rosacea treatment, expecting launch in Q1-Q2 2025, and reported $14.6 million in Q3 2024 revenues.

DelveInsight's 'Rosacea Pipeline Insight, 2024' report highlights 25+ key companies developing 25+ pipeline drugs for Rosacea, with therapies in various stages of clinical development. Key companies include Sol-Gel Technologies, Maruho Co., Ltd., AOBiome LLC, and others. Emerging therapies like Epsolay, M 1220, and BMX-010 are expected to impact the market. Regulatory approvals and collaborations are noted, such as Sol-Gel Technologies' agreement with Searchlight Pharma Inc. and Zydus Lifesciences' FDA approval for Metronidazole Topical cream.